BIO President and CEO Jim Greenwood issued statement regarding announced retirement of Dr. Margaret Hamburg. Dr. Hamburg presided over implementation of Food and Drug Administration Safety and Innovation Act and successful launch of breakthrough therapy designation program and other expansions of expedited approval pathways. These programs have proven invaluable in bringing groundbreaking new therapies to patients more efficiently, while maintaining FDA’s high standards for safety and efficacy.